Showing results (131-140 of 157) with videos related to
Sort By:
Pageof 16
Clinical Pharmacokinetics|October 23, 2024
Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision DosingMuhammad Waqar Ashraf, Satu Poikola, Mikko Neuvonen, et al.International Journal of Pharmaceutics|April 16, 2018
Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in miceVille Vartiainen, Janne Raula, Luis M Bimbo, et al.British Journal of Clinical Pharmacology|May 23, 2023
Introduction of an electrochemical point-of-care assay for quantitative determination of paracetamol in finger-prick capillary whole blood samplesJohanna Kujala, Niklas Wester, Terhi J Lohela, et al.Clinical Pharmacology and Therapeutics|June 2, 2022
Genomewide Association Study of Simvastatin PharmacokineticsAnssi J H Mykkänen, Suvi Taskinen, Mikko Neuvonen, et al.The Journal of Pharmacology and Experimental Therapeutics|March 22, 2002
Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidaseThomas E Mürdter, Godehard Friedel, Janne T Backman, et al.Journal of Cachexia, Sarcopenia and Muscle|December 13, 2017
Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscleJuha J Hulmi, Tuuli A Nissinen, Markus Räsänen, et al.Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protectionMarkus Räsänen, Joni Degerman, Tuuli A Nissinen, et al.European Journal of Clinical Pharmacology|August 12, 2016
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interactionMari Fihlman, Tuija Hemmilä, Nora M Hagelberg, et al.Clinical Pharmacology and Therapeutics|October 3, 2023
Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate RosuvastatinMinna Lehtisalo, E Katriina Tarkiainen, Mikko Neuvonen, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 23, 2021
An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivityHelinä Kahma, Laura Aurinsalo, Mikko Neuvonen, et al.Pageof 16